Dash Bio secures $30 million Series A funding led by Oak HC/FT
Dash Bio announced it has closed a $30 million Series A financing round, with Oak HC/FT serving as the lead investor. The capital will be used to expand the company’s platform that offers cloud‑style services for pharmaceutical research.
Co‑founder Dave Johnson recalled pitching the concept in the fall of 2024, noting that many venture capitalists initially found the idea of a pharma lab‑services company unappealing. Despite the early skepticism, the firm succeeded in attracting significant backing.
The new funding positions Dash Bio to accelerate its mission of providing an "Amazon Web Services of drug development" model, aiming to streamline laboratory workflows and data management for biotech and pharma partners.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Dash Bio raises $30M Series A led by Oak HC/FT”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that